UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma

Hao,Peng; Kang,Bo; Li,Yapeng; Hao,Wenqi; Ma,Feihong

doi:10.3892/mmr.2019.10322

UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma

Authors:
- Peng Hao
- Bo Kang
- Yapeng Li
- Wenqi Hao
- Feihong Ma
View Affiliations

Affiliations: Department of Urology Surgery, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Department of Central Sterile Supply, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Medical Record, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Distinguished Physician Class, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China, Department of Interventional Radiology, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154003, P.R. China
Published online on: June 3, 2019 https://doi.org/10.3892/mmr.2019.10322
Pages: 1212-1220
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is a common malignant tumor globally. The overall survival of patients with RCC is poor; one important factor is tumor heterogeneity. Ubiquitin‑conjugating enzyme E2T (UBE2T) has been reported to act as an oncogene in various types of cancer; however, its role in RCC has yet to be investigated. In the present study, UBE2T was demonstrated via reverse transcription‑quantitative PCR analysis to be significantly upregulated in RCC samples and cell lines compared with in normal tissue and cells. Additionally, UBE2T expression was significantly associated with late tumor stage and high grade in patients with RCC, and patients with high UBE2T expression exhibited poor prognosis compared with patients with low expression. Following knockdown of UBE2T in 786‑O cells using RNA interference technology, the proliferation and colony formation of cells were inhibited as determined by an MTT assay and crystal violet staining, respectively; however, the migration and invasion of 786‑O cells were not affected, as determined by wound‑healing assay and Transwell assays, respectively. Xenograft RCC tumor growth in vivo was also significantly suppressed. The expression levels of two mesenchymal cell markers, N‑cadherin and vimentin, were reduced following UBE2T knockdown, whereas E‑cadherin and fibronectin levels were increased as determined by western blotting, indicating that epithelial‑mesenchymal transition was suppressed. In addition, the phosphorylation levels of PI3K, Akt and mTOR were notably decreased following UBE2T knockdown, but were increased when UBE2T was overexpressed. Wortmannin, an Akt inhibitor, reversed the UBE2T overexpression‑induced increase in the phosphorylation of PI3K, Akt and mTOR. Similarly, the UBE2T overexpression‑induced promotion of 786‑O cell proliferation was also attenuated by wortmannin. In conclusion, UBE2T promoted the proliferation of RCC cells by regulating PI3K/Akt signaling, suggesting it may be a novel target for the treatment of patients with RCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
3	Bhatt JR and FinelliI A: Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kamps R, Brandao RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ and Romano A: Next-generation sequencing in oncology: Genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 18:E3082017. View Article : Google Scholar : PubMed/NCBI
5	Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH and Karim S: Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics. Anticancer Res. 34:1873–1884. 2014.PubMed/NCBI
6	Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 32:1968–1976. 2014. View Article : Google Scholar : PubMed/NCBI
7	Alpi AF, Chaugule V and Walden H: Mechanism and disease association of E2-conjugating enzymes: Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016. View Article : Google Scholar : PubMed/NCBI
8	Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D'Andrea AD and Dutta A: UBE2T is the E2 in the fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 23:589–596. 2006. View Article : Google Scholar : PubMed/NCBI
9	Alpi A, Langevin F, Mosedale G, Machida YJ, Dutta A and Patel KJ: UBE2T, the fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: A basis for the regulation of FANCD2 monoubiquitination. Mol Cell Biol. 27:8421–8430. 2007. View Article : Google Scholar : PubMed/NCBI
10	Richman KA, Lach FP, Abhyankar A, Donovan FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O, Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T subtype of fanconi anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
11	Mamrak NE, Shimamura A and Howlett NG: Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome fanconi anemia. Blood Rev. 31:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
12	Hira A, Yoshida K, Sato K, Okuno Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, et al: Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause fanconi anemia. Am J Hum Genet. 96:1001–1007. 2015. View Article : Google Scholar : PubMed/NCBI
13	Alter BP: Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 27:214–221. 2014. View Article : Google Scholar : PubMed/NCBI
14	Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway. Oncotarget. 7:15161–15172. 2016.PubMed/NCBI
15	Liu LP, Yand M, Peng QZ, Li MY, Zhang YS, Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53. Biochem Biophys Res Commun. 493:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wen M, Kwon Y, Wang Y, Mao JH and Wei G: Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 6:25226–25239. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Leng H, Chen H, Wang L, Jiang N, Hua X and Yu B: Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol Res. 24:361–369. 2016. View Article : Google Scholar : PubMed/NCBI
18	Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang J, Cao H, Zhang G, Li Y and Jiao Z: UBE2T knockdown inhibits gastric cancer progression. Oncotarget. 8:32639–32654. 2017.PubMed/NCBI
19	Gong YQ, Peng D, Ning XH, Yang XY, Li XS, Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
20	Ueki T, Park JH, Nishidate T, Kijima K, Hirata K, Nakamura Y and Kataqiri T: Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG and Wouters BG: Hypoxia disrupts the fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol. 101:190–197. 2011. View Article : Google Scholar : PubMed/NCBI
22	Perez-pena J, Corrales-sanchez V, Amir E, Pandiella A and Ocana A: Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Sci Rep. 7:175302017. View Article : Google Scholar : PubMed/NCBI
23	Hao J, Xu A, Xie X, Hao J, Tian T, Gao S, Xiao X and He D: Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 29:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lopez-Beltran A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Chen T, You Y, Jiang H and Wang ZZ: Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
27	Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K and Fromont G: Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol. 61:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
28	Scanlon CS, Van Tubergen EA, Inglehart RC and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
29	Tian T, Li XY and Zhang JH: mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 20:7552019. View Article : Google Scholar :
30	Faes S and Dormond O: PI3K and AKT: Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015. View Article : Google Scholar : PubMed/NCBI
31	Berquist SW, Yim K, Ryan ST, Patel SH, Eldefrawy A, Cotta BH, Bradshaw AW, Meagher MF, Bindayi A, McKay RR, et al: Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. Int J Urol. Apr 3–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
32	Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K and Demkow T: Contemporary treatment of metastatic renal cell carcinoma. Med Oncol. 35:1562018. View Article : Google Scholar : PubMed/NCBI
33	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
34	D'Avella C, Abbosh P, Pal SK and Geynisman DM: Mutations in renal cell carcinoma. Urol Oncol. Nov 23–2018.(Epub ahead of print). View Article : Google Scholar
35	Yu H, Xiang P, Pan Q, Huang Y, Xie N and Zhu W: Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
36	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
37	Brabletz T, Kalluri R, Nieto MA and Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018. View Article : Google Scholar : PubMed/NCBI
38	Dimitrova V and Arcaro A: Targeting the PI3K/Akt/mTOR signaling pathway in medulloblastoma. Curr Mol Med. 15:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
39	Cargnello M, Tcherkezian J and Roux PP: The expanding role of mTOR in cancer cell growth and proliferation. Mutagenesis. 30:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
40	Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in medullary thyroid cancer: A promising molecular target for cancer therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar : PubMed/NCBI
41	Xie C, Powell C, Yao M, Wu J and Dong Q: Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
42	Wang R, Song Y, Liu X, Wang Q, Wang Y, Li L, Kang C and Zhang Q: UBE2C induces EMT through Wnt/βcatenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of aurora-a. Int J Oncol. 50:1116–1126. 2017. View Article : Google Scholar : PubMed/NCBI
43	Jin Y, Xu K, Chen Q, Wang B, Pan J, Huang S, Wei Y and Ma H: Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT pathway. Exp Cell Res. 362:362–369. 2018. View Article : Google Scholar : PubMed/NCBI
44	Rumman M, Jung KH, Fang Z, Yan HH, Son MK, Kim SJ, Kim J, Park JH, Lim JH, Hong S and Hong SS: HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Oncotarget. 7:78029–78047. 2016. View Article : Google Scholar : PubMed/NCBI
45	Zhang GW, Tian X, Li Y, Wang ZQ, Li XD and Zhu CY: Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway. Biomed Pharmacother. 104:119–126. 2018. View Article : Google Scholar : PubMed/NCBI